Skip to main
JBIO

JBIO Stock Forecast & Price Target

JBIO Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Jade Biosciences Inc. is projected to achieve significant risk-adjusted revenue growth from its lead candidate, JADE101, with estimates increasing from $80 million in 2031 to $926 million by 2037, representing a compound annual growth rate (CAGR) of 23%. The company’s advanced research indicates that JADE101 demonstrates improved potency, affinity, and half-life compared to existing therapies, which could result in better efficacy and safety for patients. With a solid pipeline including JADE201 and JADE301, along with multiple anticipated value-inflection points, there is a strong foundation for sustained financial performance and long-term growth in the biotech sector.

Bears say

Jade Biosciences faces significant risks that could hinder its financial performance and market potential, particularly if it struggles to commercialize its therapies or achieve expected product uptake. The company reported a substantial net loss of $25 million in the third quarter of 2025, which raises concerns about its ongoing financial viability and ability to sustain operations. Additionally, delays in clinical development or regulatory approvals for its main candidates, JADE101 and JADE201, could severely impede Jade's revenue generation capabilities and overall valuation.

JBIO has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aerovate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aerovate Therapeutics Inc (JBIO) Forecast

Analysts have given JBIO a Strong Buy based on their latest research and market trends.

According to 5 analysts, JBIO has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aerovate Therapeutics Inc (JBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.